[Current treatment concepts in heparin-induced thrombocytopenia].
Ranze
O
O
Abteilung Transfusionsmedizin, Ernst-Moritz-Arndt Universität Greifswald. ranze@mail.uni-greifswald.de
Greinacher
A
A
D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000009:adverse effects; D006629:Hirudins / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D011247:Pregnancy; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; D006629:Hirudins; C035838:danaparoid
Aktuelle Behandlungskonzepte bei Heparin-induzierter Thrombozytopenie.